Model identifies risk of serious complications following surgery
Research News Release
EurekAlert! provides eligible reporters with free access to embargoed and breaking news releases.
Eligibility GuidelinesEurekAlert! offers eligible public information officers paid access to a reliable news release distribution service.
Eligibility GuidelinesEurekAlert! is a service of the American Association for the Advancement of Science.
A web-based tool developed by Jefferson researchers predicts individualized risk for stroke, other grave post-surgical complications.
Early detection could reduce the number of African Americans dying from liver cancer, but current screening guidelines may not find cancer soon enough in this community, according to a study published in Cancer in February.
According to a new study published in The American Journal of Human Genetics, more than one third of genetic variants that increase the risk of coronary artery disease regulate the expression of genes in the liver. These variants have an impact on the expression of genes regulating cholesterol metabolism, among other things. The findings provide valuable new insight into the genetics of coronary artery disease.
Scientists at the University of Cambridge have used a technique to grow bile duct organoids - often referred to as 'mini-organs' - in the lab and shown that these can be used to repair damaged human livers. This is the first time that the technique has been used on human organs.
The pandemic has seen a significant, alarming trend of increased alcohol use and abuse - especially among younger adults, males and those who lost jobs - the University of Arizona Health Sciences reports. New research led by William 'Scott' Killgore, PhD, psychiatry professor in the UArizona College of Medicine - Tucson and Social, Cognitive and Affective Neuroscience Lab director, found hazardous alcohol use and dependence increased every month for those under lockdowns compared to those not under restrictions.
Researchers have discovered that the use of Cytoglobin (CYGB) as an intravenous drug could delay liver fibrosis progression in mice. CYGB, discovered in 2001 by Professor Norifumi Kawada, is present in hepatic stellate cells, the cells that produce fibrotic molecules such as collagens when the liver has acute or chronic inflammation induced by different etiologies. The enhancement of CYGB on these cells or the injection of recombinant CYGB has the effect of suppressing liver damage and cirrhosis.
In a study published in Nature Communications, cancer researchers at Kanazawa University identify mechanisms by which malignant tumor cells extend their toxicity to distinct cell types and in turn help them spread.
A Mayo Clinic team, led by Rahmi Oklu, M.D., Ph.D., a vascular and interventional radiologist at Mayo Clinic, in collaboration with Samir Mitragotri, Ph.D., of Harvard University, report the development of a new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab. This discovery could solve a problem that has long plagued drug delivery to tumors.
New research has shown that results of blood tests routinely performed by GPs everywhere contain a hidden fingerprint that can identify people silently developing potentially fatal liver cirrhosis. The researchers have developed an algorithm to detect this fingerprint that could be freely installed on any clinical computer, making this a low-cost way for GPs to carry out large scale screening using patient data they already hold.
Hebrew Unievrsity researchers have found a less invasive and more accurate options for diagnoses using a simple blood test that detects DNA fragments.